Skip to main content
SpringerLink
Log in

Relationship between prostate-specific antigen, prostate volume, retention volume and age in benign prostatic hypertrophy (BPH)

  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

The relationship between plasma PSA, prostatic adenoma mass (AM), retention volume (RV) and age was studied in 112 men with benign prostatic hypertrophy (BPH). Their age ranged from 48 to 85 years. Mean PSA was 6.9 ng/ml (SD 6.6) and did not exceed 10 ng/ml in 81.2% of the patients. Mean AM and RV were 66.2 g (SD 36) and 51.7 ml (SD 1.3), respectively. Increase in PSA level was influenced mainly by RV (r=0.53) but was found to correlate weakly with AM (r=0.34) which in turn showed low correlation with RV (r=0.32). Age did not correlate with PSA, AM and RV (r>=0.1). AM and RV influence PSA levels independently and large inter-patient differences are well characterized by SD values.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bentvelsen, F. M., Van Den Ouden, D., Schroeder, F. H.: Prostate specific antigen in screening for recurrence following radical prostatectomy for localized prostatic cancer.Br. J. Urol., 72, 88 (1993).

    PubMed  CAS  Google Scholar 

  2. Dutkiewicz, S., Stawarz, B., Łypka, A., Zieliński, H.: The prognostic value of prostate-specific antigen and prostatic acid phosphatase in serum of patients with prostate cancer after orchidectomy.Int. Urol. Nephrol., 24, 409 (1992).

    Article  PubMed  CAS  Google Scholar 

  3. Dutkiewicz, S., Stepień, K., Witeska, A. Diagnostic value of prostatic specific antigen (PSA) in comparison to prostatic acid phosphatase (PAP) in prostatic cancer and adenoma.Wiad. Lek., 45, 750 (1992).

    PubMed  CAS  Google Scholar 

  4. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J., Freiha, F. S., Redwine, E.: Prostatespecific antigen as a serum marker for adenocarcinoma of the prostate.N. Engl. J. Med., 317, 909 (1987).

    Article  PubMed  CAS  Google Scholar 

  5. Oesterling, J. E.: Prostate specific antigen: A critical assessment of the most useful tumour marker for adenocarcinoma of the prostate.J. Urol., 145, 907 (1991).

    PubMed  CAS  Google Scholar 

  6. Armitage, T. G., Cooper, E. H., Newling, W. W., Robinson, M. R. G., Appleyard, J.: The value of the measurement of serum prostate specific antigen in patients with benign prostate hyperplasia and untreated prostate cancer.Br. J. Urol., 62, 584 (1988).

    PubMed  CAS  Google Scholar 

  7. Myrtle, J. E., Kimley, P. G., Ivor, L. P., Brun, J. F.: Clinical utility of prostate-specific antigen (PSA) in the management of prostate cancer. Adv. Cancer Diag., Hybritech. Inc. 1986.

  8. Chan, D. W., Bruzek, D. J., Oesterling, J. E., Rock, R. C., Walsh, P. C.: Prostate-specific antigen as a marker for prostatic cancer: A monoclonal and polyclonal immunoassay compared.Clin. Chem., 33, 1916 (1987).

    PubMed  CAS  Google Scholar 

  9. Marczyńska, A., Kulpa, J.: Prostate-specific antigen (PSA) in patients with prostate cancer.Urol. Pol., 45, 69 (1992).

    Google Scholar 

  10. Weber, J. P., Oesterling, J. E., Peters, C. A. Partin, A. W., Chan, D. W., Walsh, P. C.: The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia.J. Urol., 141, 987 (1989).

    PubMed  CAS  Google Scholar 

  11. Shearer, R. J.: Prostatic specific antigen.Br. J. Urol., 67, 1 (1991).

    Article  PubMed  CAS  Google Scholar 

  12. Garraway, W. M., Collins, G. N., Lee, R. J.: High prevalence of benign prostatic hypertrophy in the community.Lancet, 338, 469 (1991).

    Article  PubMed  CAS  Google Scholar 

  13. Collins, G. N., Lee, R. J., McKelvie, G. B., Rogers, A. C. N., Hehir, M.: Relationship between prostate specific antigen, prostate volume and age in the benign prostate.Br. J. Urol., 71, 445 (1993).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Central Clinical Hospital, Health Administration of the Capital, Ministry of Internal Affairs, Warsaw, Poland

    S. Dutkiewicz, A. Witeska & K. Stepien

Authors
  1. S. Dutkiewicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Witeska
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Stepien
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dutkiewicz, S., Witeska, A. & Stepien, K. Relationship between prostate-specific antigen, prostate volume, retention volume and age in benign prostatic hypertrophy (BPH). International Urology and Nephrology 27, 763–768 (1995). https://doi.org/10.1007/BF02552144

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02552144

Keywords

Search

Navigation